{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT, MRI or X-ray: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","groups":[{"description":"Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nbelinostat: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Belinostat)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee","type":"PRIMARY","unitOfMeasure":"percentage of participants"}